Adipose Tissue Pre and Post Bariatric Surgery
- Conditions
- Obesity
- Interventions
- Procedure: Bariatric surgeryOther: Blood samplingOther: Blood pressureOther: Anthropometric measurementsOther: Body compositionOther: Resting metabolic rateOther: Food intakeProcedure: Adipose tissue biopsy
- Registration Number
- NCT05304325
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Brief Summary
Published data suggest that inflammation and fibrosis of adipose tissue could be factors favoring the development of insulin resistance in obese individuals and that a decrease in the activity of the AMP-activity kinase protein (AMPK) could lead to these dysfunctions. However, very few data are available in humans.
There is also growing interest in persistent organic pollutants (POPs) as a cardiometabolic and type 2 diabetes (T2D) risk factor. There is some evidence to suggest that POPs directly contribute to lipid metabolism dysfunction and insulin resistance. Additionally, POPs are stocked in adipose tissue. The accumulation of POPs in adipose tissue therefore limits their bioavailability to other organs, thus reducing their systemic toxicity. It has been observed that a large amplitude weight loss leads to a significant increase in POPs in the blood.
The goal of this project is to identify adipose tissue factors/dysfunctions that contribute to insulin resistance and type 2 diabetes associated with obesity in humans and thus raise avenues for screening and treatment of these metabolic complications. More specifically, the objectives are:
* To study the relationship between AMPK, fibrosis and inflammation of adipose tissue and their role in the development of insulin resistance and T2D associated with obesity;
* To examine the relationship between POPs and the cardiometabolic profile.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 98
- Awaiting bariatric surgery
- BMI ≥ 35 kg/m2 without cardiometabolic complications or ≥ 30 kg/m2 if presence of type 2 diabetes or hypertension
- ≥ 18 years old
- Non smoker
- Sedentary (less than 3 hours of regular physical activity per week)
- Type 1 diabetes
- Acute event in the last 3 months (myocardial infarction, cerebrovascular hemorrhage or transient cerebral ischemia, unstable angina, peripheral vascular disease, revascularization or angioplasty, recent hospitalization for more than 4 days)
- Infection in the last month (fever, antibiotics treatment)
- Cancer in the last 3 years
- Chronic inflammatory disease
- Pharmacologic treatment (any medication affecting glucose metabolism (except those for diabetes), hypotensive medication unless stable dose for at least 1 month, lipid-lowering medication unless stable dose for at least 1 month)
- Uncontrolled disease of pituitary or thyroid gland
- Bleeding disorders
- Alcohol or drug abuses
- Claustrophobia
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Obese insulin-resistant Food intake - Obese with type 2 diabetes Anthropometric measurements - Obese with type 2 diabetes Body composition - Obese insulin-sensitive Resting metabolic rate - Obese with type 2 diabetes Blood pressure - Obese with type 2 diabetes Bariatric surgery - Obese with type 2 diabetes Blood sampling - Obese with type 2 diabetes Resting metabolic rate - Obese insulin-sensitive Bariatric surgery - Obese with type 2 diabetes Food intake - Obese insulin-resistant Resting metabolic rate - Obese insulin-resistant Adipose tissue biopsy - Obese insulin-sensitive Anthropometric measurements - Obese insulin-resistant Blood pressure - Obese insulin-sensitive Adipose tissue biopsy - Obese insulin-resistant Blood sampling - Obese insulin-resistant Anthropometric measurements - Obese with type 2 diabetes Adipose tissue biopsy - Obese insulin-sensitive Blood pressure - Obese insulin-sensitive Body composition - Obese insulin-resistant Body composition - Obese insulin-sensitive Blood sampling - Obese insulin-sensitive Food intake - Obese insulin-resistant Bariatric surgery -
- Primary Outcome Measures
Name Time Method Adipose tissue fibrosis using qRT-PCR, immunoblotting, histochemistry and immunohistochemistry 6 months after bariatric surgery
- Secondary Outcome Measures
Name Time Method Food quality using the Food Frequency Questionnaire 6 months after bariatric surgery Persistant organic pollutants measured by high-resolution chromatography combined with high-resolution mass spectrometry 6 months after bariatric surgery AMP-activated protein kinase 6 months after bariatric surgery Calory intake 6 months after bariatric surgery Inflammation in adipose tissue using qRT-PCR, immunoblotting and immunohistochemistry 6 months after bariatric surgery
Trial Locations
- Locations (1)
Institut de recherches cliniques de Montréal
🇨🇦Montreal, Quebec, Canada